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Tetrahydrobiopterin (BH4) is an essential cofactor for
the nitric oxide (NO) synthases and represents a critical
determinant of NO production. BH4 depletion during
ischemia leads to the uncoupling of the synthases, thus
contributing to reperfusion injury due to increased
superoxide formation. To examine whether BH4
supplementation attenuates ischemia–reperfusion injury,
we clamped the left renal arteries of male Lewis rats
immediately following right-side nephrectomy. BH4 tissue
levels significantly decreased after 45min of warm
ischemia compared with levels in non-ischemic controls.
Histopathology demonstrated significant tubular damage
and increased peroxynitrite formation. Intravital fluorescent
microscopy found perfusion deficits in the microvasculature
and leakage of the capillary mesh. Supplemental BH4
treatment before ischemia significantly reduced ischemia-
induced renal dysfunction, and decreased tubular histologic
injury scores and peroxynitrite generation. BH4 also
significantly improved microcirculatory parameters such as
functional capillary density and diameter. These protective
effects of BH4 on microvasculature were significantly
correlated with its ability to abolish peroxynitrite formation.
We suggest that BH4 significantly protects against acute
renal failure following ischemia reperfusion. Whether BH4
has a therapeutic potential will require more direct testing
in humans.
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Renal ischemia–reperfusion injury (IRI) still represents
a major clinical complication after both transplantation
and renal surgery.1 Although advanced surgical techniques,
novel immunosuppressive regimens, and more effective
prophylaxis of infections resulted in markedly improved
outcomes, 2–50% of all kidney transplants still manifest
some degree of early dysfunction, leading to the clinical
syndrome of delayed graft function.2 This form of acute
renal failure3 (ARF) following ischemia and reperfusion
results in post-transplantation oliguria, increased allograft
immunogenicity, and risk of acute rejection episodes as well
as decreased long-term survival.4 In addition, it has been
shown that IRI is also the main cause of ARF after major
renal surgery and trauma.5–7 IRI entails various patho-
physiological events including microcirculatory disorders,
endothelial cell activation, and expression of proinflamma-
tory cytokines and adhesion molecules as well as loss of
endothelial integrity.8
Ischemia and, paradoxically, the reinstitution of blood
supply during reperfusion thereby cause not only the
resumption of metabolic functions but also the generation
of deleterious oxygen-free radicals such as superoxide (O2),
peroxynitrite (ONOO), and nitric oxide (NO). NO is
produced by a family of enzymes called the nitric oxide
synthases (NOS) that convert the amino acid L-arginine and
O2 to L-citrulline and NO. This NADPH-consuming enzy-
matic reaction requires Ca2þ /calmodulin, flavin adenine
dinucleotide, flavin mononucleotide, and heme and tetra-
hydrobiopterin (BH4) as cofactors.
Under physiological conditions, NO has been shown
to be an important mediator of vascular homeostasis,
inflammation, and neurotransmission.9,10 NO generation
can attenuate renal damage due to inhibition of platelet
aggregation and regulation of neutrophil recruitment by
inhibiting the expression of adhesion molecules. Moreover,
exogenous NO was shown to diminish IRI after solid organ
transplantation.11,12
However, it has also been stated that excessive production
of NO predominantly by the inducible NOS isoform can lead
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to the disruption of active cytoskeleton, thus resulting in
proximal tubular cell detachment and tubular obstruction.13
Furthermore, an increase in NO during inflammatory
responses has also been linked to neutrophil recruitment,
increased production of inflammatory cytokines, and in-
creased ONOO and O2
 formation, both potent oxidants
that modify proteins by forming 3-nitrotyrosine.14 Thus, the
precise role of NO generated during renal ischemia and
reperfusion is discussed controversially and is still under
debate.
BH4 as an essential NOS cofactor has profound effects on
the structure of all NOS isoforms by stabilizing the active
dimeric form of the enzyme and increasing substrate affinity.
Furthermore, BH4 is highly redox-sensitive and readily
oxidized. Oxidative stress induced by IRI has been shown
to deplete intracellular BH4 stores below a critical threshold,
resulting in an uncoupling of the NOS enzyme after which
the heme group can directly reduce oxygen and release
superoxide (O2
) instead of NO.13,15,16 Superoxide in concert
with other highly reactive free radicals then form a cytotoxic
cocktail capable of initiating inflammatory pathways con-
tributing to IRI.17
The aim of this study was to determine whether BH4
supplementation would exert beneficial effects on IRI in
terms of improvement of microvascular perfusion, histo-
logical tissue damage, and decrease in the generation of
oxygen-free radicals in the kidneys undergoing renal artery
clamping. On the basis of our results, we hypothesize that
BH4 might be a novel promising therapeutic agent to reduce
delayed graft function in kidney transplants as well as ARF
after major renal surgery.
RESULTS
Renal BH4 tissue levels after ischemia and reperfusion
Total renal biopterin and BH4 tissue levels were assessed
by high-performance liquid chromatography. Values are
expressed as mean±s.e.m. (n¼ 6 animals per group) in
pmol/mg protein. Forty-five minutes of ischemia (I/R) led
to a significant decrease in total biopterin levels (45 minI:
12.68±3.77) compared with non-ischemic controls (control:
29.53±3.20; Po0.01). This decrease was maintained
throughout the entire observation/reperfusion period
(15 minR: 12.47±2.77; 2hR: 12.77±2.11; 7dR: 10.17±1.21;
Figure 1a). Treatment with BH4 (I/RþBH4) was associated
with a massive increase in kidney biopterin concentrations
following 45 min of ischemia (45 minþBH4: 2279±672), as
well as after 15 min (15 minR: 2211±441.2) and 2 h (2 hR:
2289±298.7) of reperfusion (Po0.001) (Figure 1b). This
confirmed that the administered BH4 reached the kidney
during the reperfusion period. The high variability in the
I/RþBH4 group was caused by animal-to-animal variation
in response to BH4 treatment rather than by variability in
the measurement method, which showed a coefficient of
variation of 3.1±0.8% (mean±s.d. of triplicate variation
of kidney samples of six BH4-treated animals).
Effects of BH4 on kidney microcirculation
Following 45 min of ischemia and 120 min of reperfusion,
kidneys were analyzed by means of intravital fluorescence
microscopy (IVM). To assess and quantify ischemia-induced
microvascular injury, functional defects and the potential
protective effects of BH4 microcirculatory parameters such as
functional capillary density (FCD) and capillary diameter
(CD) were determined. FCD is defined as the length of all
blood cell-perfused nutritive capillaries per observation area,
and CD as the largest distance of two opposite capillary walls
per observation area. Forty-five minutes of ischemia (I/R)
caused significant perfusion deficits with leakage of the
capillary mesh (Figure 2b and d; supplementary online
video 1), compared with the homogeneous perfusion patterns
of baseline controls (Figure 2a and d; supplementary online
video 2). Mean FCD in controls was 429.9±3.33 cm1,
which was significantly decreased after 45 min of warm
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Figure 1 |BH4 tissue levels. (a) Total BH4 tissue levels in kidneys
subjected to 45min of ischemia (I) and up to 7 days of reperfusion (R).
Ischemia significantly decreased BH4 levels. During reperfusion,
BH4 levels remained low throughout the entire observation
period. Data are expressed as pmol biopterin per mg protein.
(b) Total biopterin tissue levels in kidneys treated with 20mg/kg
tetrahydrobiopterin before ischemia and reperfusion. Peak BH4
levels were determined after 45min of ischemia and 15min and
2 h after reperfusion. Po0.001 as compared with controls and
after BH4 supplementation. Data are means±s.e.m.; n¼ 6.
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ischemia (I/R) 376.2±8.10 cm1 (Po0.01). In parallel,
ischemia significantly decreased intercapillary distance (I/R)
2.50±0.08 cm1 compared with controls 4.0±0.13 cm1
(Po0.01). BH4 administration before ischemia, however,
significantly improved all microcirculatory parameters re-
sulting in increased FCD (I/RþBH4) 410.3±2.72 cm1
(Po0.01) and increased CD (I/RþBH4) 3.63±0.08 cm1
(Po0.01), comparable with non-ischemic controls (Figure 2c
and d; supplementary online video 3).
Histopathology
Histological findings determined by hematoxylin and eosin
staining were classified using the Solez score.18 Kidneys
undergoing 45 min of renal artery clamping and 7 days of
reperfusion (I/R) thereby showed significant ischemia-
induced damage particularly within the renal tubuli,
compared with non-ischemic controls, including detachment
of the tubulus epithelial cells (I/R: 1.40±0.10 versus control:
0.39±0.08; Po0.01), interstitial edema (I/R: 1.25±0.13
versus control: 0.37±0.07; Po0.01), and tubular cell casts
(I/R: 2.25±0.24 versus control: 0.42±0.07; Po0.01) (Figure
3b and d) (Figure 3a and d). In contrast, renal histology
obtained after BH4 supplementation revealed significantly
diminished changes and reduced quantitative renal tissue
damage scores (epithelial detachment: I/R 1.40±0.10 versus
I/RþBH4: 0.45±0.06; Po0.01; interstitial edema: I/R:
1.25±0.13 versus I/RþBH4: 0.51±0.08; Po0.01; tubular
cell cast: I/R: 2.25±0.24 versus I/RþBH4: 1.33±0.11;
Po0.01) (Figure 3c and d).
Peroxynitrite formation
The nitrosylation of tyrosine is paradigmatic for the reaction
of peroxynitrite (ONOO) with aromatic amino acids and is
therefore an indirect marker for this strong oxidative agent.
Immunostaining for nitrotyrosine was thus performed to
indirectly estimate peroxynitrite generation (Figure 4). Com-
pared with non-ischemic controls (Figure 4a), peroxynitrite
formation and hence nitrotyrosine staining were significantly
increased following 45 min of warm ischemia (Figure 4b),
which could be abrogated almost entirely by BH4 treatment
(Figure 4c).
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Figure 2 | Intravital fluorescence microscopy. (a) Kidney microcirculation in non-ischemic controls lacks signs of microvascular
injury. (b) In contrast, significant microvascular impairment was evident following 45min of ischemia. (c) BH4 supplementation shows
reversal of microcirculatory changes. Original magnification  350. (d) Mean functional capillary density and capillary diameter.
BH4 significantly improved microcirculatory parameters compared with no treatment (I/R). Data presented as means±s.e.m. (Po0.01) n¼ 6.
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For quantification purposes, the product of the propor-
tion of positive cells and the staining intensity was calculated,
yielding a total immunostaining score ranging from 0 to 12
(Figure 4d). Immunostaining was significantly higher in
untreated kidneys (I/R: 7.56±0.45) compared with BH4-
treated kidneys (I/RþBH4: 2.22±0.45) or non-ischemic
controls (control: 0.85±0.54). In addition, intragraft perox-
ynitrite generation correlated significantly with the impair-
ment of renal microcirculation and FCD scores. (Spearman:
r¼0.58; Po0.01; data from Figure 4d). A similar staining
pattern was also observed at 2 h following reperfusion (I/R:
5.53±0.88; I/RþBH4: 1.65±0.58; control: 1.08±0.49),
whereas histomorphology only revealed moderate tissue
edema but no other morphologic changes such as tubular
cell cast or detachment of tubulus epithelial cells at such an
early time point following ischemic injury (data not shown).
Effect of BH4 treatment on renal function
Renal function was assessed using serum creatinine and urea
as indirect parameters of glomerular function. Both para-
meters were significantly increased after renal ischemia in
untreated animals (I/R) after 24 h (Cr: 2.14±0.81 mg/dl; U:
286.67±55.28 mg/dl) and 48 h (Cr: 1.34±0.24 mg/dl; U:
196.02±40.00 mg/dl) following reperfusion compared with
non-ischemic sham-operated controls (sham) Cr:
0.65±0.18 mg/dl; U: 82.58±14.25 mg/dl at 24 h and
Cr: 0.44±0.24 mg/dl; U: 68.27±21.94 mg/dl at 48 h. The
administration of a single dose of BH4 (I/RþBH4) before
ischemia resulted in significantly improved renal function and
reduced serum creatinine and urea levels Cr: 0.58±0.19 mg/dl;
U: 84.10±20.70 mg/dl at 24 h and Cr: 0.48±0.13 mg/dl; U:
81.77±22.48 mg/dl at 48 h after reperfusion (Figure 5a and b).
In line with animals subjected to ischemic injury, only rats
undergoing life-supporting kidney transplantation following
bilateral nephrectomy (TX) also showed significant increases
in serum creatinine and urea after 24 h (Cr: 2.41±0.43 mg/dl;
U: 292.0±51.40 mg/dl), 48 h (Cr: 3.75±1.20 mg/dl; U:
452.40±202.5 mg/dl), and 7 days (Cr: 1.40±0.13 mg/dl; U:
210.50±226.3 mg/dl) after transplantation without treat-
ment. The administration of a single dose of BH4 (20 mg/kg
per body weight) to the donor and recipient before organ
recovery and revascularization (TXþBH4), respectively,
resulted in significantly improved renal function at 24 h
(Cr: 1.53±0.92 mg/dl; U: 266.50±71.55 mg/dl), 48 h (Cr:
1.65±0.73 mg/dl; U: 341.50±230.20 mg/dl), and 7 days (Cr:
0.56±0.20; U: 119.60±44.89 mg/dl) after transplantation. In
addition to improved graft function, BH4 therapy also
increased animal survival rates from 33.2% in the untreated
control group (TX) to 66.7% in the BH4-treated group
(TXþBH4) (Po0.01).
DISCUSSION
In this study, we were able to show that BH4 supplementa-
tion significantly protects kidneys from IRI. Moreover,
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Figure 3 |Histopathology (hematoxylin and eosin staining). (a) Non-ischemic controls. (b) Tubular cell cast, interstitial edema, epithelial
detachment, and expansion of Bowman’s capsule were observed in kidneys undergoing ischemia and 7 days of reperfusion. (c, d) BH4
supplementation significantly improved semiquantitative histological scores. Data presented as means±s.e.m. (Po0.01).
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BH4 restores ischemia-induced microcirculatory disorders,
diminishes histological damage such as epithelial detach-
ment, tubular cell cast, and interstitial edema, and abrogates
peroxynitrite formation consequently resulting in improved
renal function.
It has been previously shown that BH4, a cofactor of all
NOS isoforms, is one of the most powerful naturally
occurring reducing substances having direct antioxidant
effects contributing to its cytoprotective action.19 Several
studies have suggested that the availability of BH4 is essential
for the formation and stabilization of NOS. The absence of
BH4 results in an uncoupling of the NOS enzyme and
subsequently causes superoxide formation instead of NO,
thereby contributing substantially to oxidative injury follow-
ing ischemia reperfusion.20
The loss of BH4 is likely the result of oxidative
degradation secondary to the formation of oxidants and
oxygen-free radicals that are enhanced during kidney
ischemia and reperfusion. In particular, the endothelium is
considered to generate free radicals during IRI. Furthermore,
oxyradical injury alters the redox state of endothelial cells and
thus impairs BH4 availability, as the biosynthesis of BH4
depends on a normal cellular redox state.21 In this study, BH4
concentrations were found to be significantly decreased
following 45 min of warm ischemia compared with non-
ischemic controls; however, this could be reversed sufficiently
by a single dose of exogenous BH4 delivery.
We therefore hypothesized that: (i) BH4 depletion in
post-ischemic kidneys may lead to the uncoupling of NOS,
increased peroxynitrite (ONOO) formation, and loss of
microcirculatory integrity resulting in impaired renal func-
tion and (ii) that BH4 supplementation would be effective in
restoring these alterations. To examine precisely the role of
BH4 in post-ischemic kidney microcirculation, studies were
performed in a rat kidney ischemia–reperfusion model using
the renal pedicle clamp approach. Clinical effects in terms of
improved renal function were additionally assessed in a rat
kidney transplant model.
One of the hallmarks of ARF and delayed graft function
are ischemia–reperfusion-related disturbances in microcircu-
lation with subsequent endothelial dysfunction, enhanced
leukocyte–endothelial interaction, and hypoxic tissue damage.22,23
Certainly, endothelial injury and peritubular capillary dysfunction
may initiate and extend the pathogenesis of ARF, and also
contribute to ischemic forms of ARF by compromising renal
vascular responsiveness and tubule function.24 In addition,
localized alterations in kidney blood flow persist after
ischemic injury and have a major role in the extension of
ischemic injury following reperfusion. Congestion in renal
microcirculation, especially in the capillaries of the outer
medullary vasa recta, contributes to deficits in oxygen and
substrate delivery.3,25 As microcirculatory dysfunction is a
common feature of various forms of renal injury, IVM has
become the preferred and unique mode of documenting
and directly monitoring changes in peritubular capillary flow
following renal ischemia.26
Microcirculation as assessed by IVM in our study was
significantly impaired in post-ischemic kidneys reflected by
persistently reduced FCD and CD. This impairment might
occur secondary to a loss of NO production from NOS with a
shift of the enzyme toward the generation of O2
 instead of
NO. This shift may be triggered by the observed near-total
depletion of BH4 during ischemia.27 Exogenous BH4
treatment probably restores NO production from NOS and
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Figure 4 | Immunostaining for nitrotyrosine of kidneys
with ischemia–reperfusion injury. (a) Non-ischemic controls.
(b) Ischemia resulted in prominent kidney nitrotyrosine staining
as observed on day 7 after reperfusion. (c) This staining was
abolished by BH4 treatment. Original magnification  200.
(d) Quantitative immunostaining score as the product of
the proportion of positive cells and the staining intensity.
Data presented as means±s.e.m. (Po0.001).
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therefore enhanced the post-ischemic recovery of kidneys.
Thus, it is reasonable to speculate that BH4 levels are a key
factor modulating NOS activity, NO production, peroxyni-
trite generation, and microcirculation in post-ischemic
kidneys.
Indeed, in this study, BH4 supplementation not only
attenuated microcirculatory damage but also significantly
decreased peroxynitrite formation, as reflected by diminished
nitrotyrosine staining scores.
Peroxynitrite is generated by the rapid interaction of
superoxide anions with NO and has been associated with
various deleterious effects on both cellular and tissue
function including increased oxidative reactions, lipid
peroxidation, and reduction of plasma antioxidants.28,29
Nitration of protein tyrosine residues leads to the formation
of 3-nitrotyrosine, and thus may be considered as an indirect
marker of peroxynitrite-dependent oxidative damage.30 The
generation of oxygen-free radicals is increased during
reperfusion, depending on the severity and duration of the
preceding ischemic period, and subsequently might also
increase peroxynitrite formation.31 This is in accord with
recent data showing that reduced peritubular capillary
perfusion may contribute to the generation of tubular
epithelial oxidant generation. Wu and Mayeux24 showed that
both reactive oxygen species32 and reactive nitrogen species
were significantly increased in the tubular epithelium
following a decrease in capillary perfusion resulting in a
microenvironment that promotes oxidant generation and
tubular injury. Also in line with this suggestion, 45 min of
warm ischemia in this study revealed a significant increase in
peroxynitrite formation and hence nitrotyrosine staining
compared with non-ischemic controls, which significantly
correlated with microcirculatory defects. Thus, our results
showing decreased nitrotyrosine immunostaining owing to
BH4 supplementation indicate that BH4 prevents the
tyrosine-nitrating properties of peroxynitrite following IRI,
leading to overall reduced injury. Therefore, BH4 may be
considered to be protective against manifestations of
oxidative and nitrosative stress in this experimental model
of renal IRI.
In this regard, apart from the protective effects on
microcirculation and peroxynitrite formation, BH4 supple-
mentation also significantly attenuated histopathologic
tubular cell damage and improved kidney function as
reflected by attenuated creatinine and urea levels during the
early period after ischemia and reperfusion. Our data are also
in line with previous findings by Kakoki et al.33 who were the
first to show, using a similar model of ischemic ARF and
treatment regimen, that a single oral dose of BH4
administered before ischemia markedly improved acetylcho-
line-induced vasorelaxation and NO release in the isolated
perfused kidney. In addition, exogenous supplementation of
BH4 in their study restored calcium-dependent NOS activity,
immunoreactivity of endothelial NOS dimers, renal excretory
function, and histomorphologic changes.33 Recent evidence
in the literature further supports the concept that BH4
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treatment has favorable actions in animals with renal
disease.34 In addition, significantly improved graft function
after renal transplantation in BH4-treated recipients, as
shown in our study, further substantiates the clinical
potential of BH4 supplementation to minimize IRI.
Several human studies have also assessed the beneficial
effects of BH4 on endothelial dysfunction. It has been shown
that BH4 supplementation improves and corrects endothe-
lium-dependent vasodilatation in patients with coronary
artery disease,35 type II diabetes mellitus,36 hypercholester-
inemia,37 hypertension and in smokers.38 Furthermore, BH4
prevents kidneys from IRI in human form.39 BH4 can thereby
restore the proper redox state in vascular cells by modulating
the relative expression of NOS leading to the proposal that a
deficiency in BH4 and defective NOS catalysis underlies
endothelial dysfunction in these states. However, although
the models and protocols are different in some situations, the
protective effects of BH4 could be mediated by the direct
improvement of NOS catalysis, possibly by the restoration of
BH4 deficiency, whereas in others they might be mediated by
its direct antioxidant effect. Further work will be required to
completely understand which of the two actions of BH4 is
more important in ischemia-induced ARF.
In summary, our data suggest that exogenous BH4
treatment is able to protect kidneys from IRI, by significantly
decreasing microvascular changes, histological damage, and
peroxynitrite formation and improving renal function para-
meters. Therefore, BH4 might provide a novel and potent
therapeutic option to prevent delayed graft function following
kidney transplantation as well as ARF after major surgery or
trauma. The clinical availability of BH4 might further facilitate
rapid clinical translation of the present findings.
MATERIALS AND METHODS
Animal experiments – renal ischemia/reperfusion
Male inbred Lewis rats with a body weight of 200–250 g were
obtained from Harlan Winkelmann (Borchen, Germany) and used
for ischemia–reperfusion and transplant experiments. All animals
received human care in compliance with the ‘Principles of
Laboratory Animal Care’ formulated by the National Society for
Medical Research and the ‘Guide for the Care and Use of Laboratory
Animals’ prepared by the National Academy of Sciences and
published by the National Institutes of Health (NIH Publication
no. 86-23, revised 1985). All experiments were approved by the
Austrian Ministry of Education, Science and Culture (BMBWK-
66011/0067-II/10b/2008). As described in detail previously, after
right-sided nephrectomy, rats were subjected to left renal occlusion
for 45 min using artery clips to clamp the renal artery. Reperfusion
commenced once the arterial clips were removed. Occlusion was
verified visually by a change in the color of the kidneys to a paler
shade and reperfusion by a blush. At the end of all experiments,
animals were killed by an overdose of anesthetics.
Renal transplantation
Orthotopic renal transplantation in male inbred Lewis rats
was performed as previously described.40 Briefly, after bilateral
nephrectomy, a syngeneic kidney is transplanted in the orthotopic
position. The University of Wisconsin solution was used for cold
(1–41C) preservation and storage (120±30 min). Revascularization
was performed within 20 min (±3 min) using a modified non-
suture cuff technique.
Experimental groups
To evaluate the effect of BH4 on IRI and ischemic ARF following
transplantation, respectively, animals were divided into five groups.
Animals in the first group received 20 mg/kg per body weight
of BH4 intramuscularly, 15 min before renal artery clamping
(I/RþBH4), whereas those in the second group were given an
equal volume of 0.9% normal saline (I/R). Sham-operated animals
served as controls (sham). In the transplanted group, both donor
and recipient received 20 mg/kg per body weight of BH4 intra-
muscularly, 15 min before organ recovery and revascularization
(TxþBH4). Saline-treated recipients served as controls (Tx).
Intravital fluorescence microscopy
IVM was used to analyze kidney microcirculation by means of FCD
and CDs after 2-h of reperfusion. FCD was defined as the
cumulative length of all blood cell perfused nutritive capillaries
per observation area and CD as the largest distance between two
opposite capillary walls per observation area. FCD and CD are
expressed as cm/cm2 (cm1).27,41 IVM was performed using an
inverted IX-70 microscope (Olympus, Nagano, Japan). To enhance
the contrast of the microvessels, 0.3 ml of a 0.4% fluorescein-
isothiocyanate-labeled dextran (molecular weight 150,000 (Da);
50 lg/kg per body weight; SIGMA, Deisenhofen, Germany) was
injected through the penile vein. Confocal microscopy was
performed with a microlens-enhanced Nipkow disk-based system
UlraVIEW RS software (Perkin-Elmer GmbH, Vienna, Austria).
Selection of observation areas as well as image acquisition was
blinded. Images consisted of a z-stack of 20 planes acquired with a
 40 objective at a wavelength of 488 nm. For each rat, five videos of
10 s each were captured at B12 frames per second to analyze and
determine perfusion in the vessels. From each video, one randomly
selected picture displaying a minimum of three vessels was analyzed
in terms of FCD and CD as described above. Quantitative image
analysis was performed with PicEd Cora (JOMESA, Munich,
Germany) software.
Histological assessment of renal injury
For histology, tissue samples were fixed in 10% formaldehyde,
embedded in paraffin, and stained with hematoxylin and eosin. A
semiquantitative histologic analysis was performed. Twenty tubules
or glomeruli in each kidney were randomly selected at  400
magnification, and the degree of renal damage was scored using the
renal injury scoring system reported by Solez et al.18 We calculated
the mean renal injury score in each rat and then averaged the scores
for each group. All sections were examined by a single pathologist
(PO) in a blinded manner. Tissue samples were examined for the
presence of expansion of Bowman’s space, interstitial edema,
epithelial detachment, and tubular cells casts. Renal morphologic
changes were graded on a scale of 0 to 3þ : 0, normal; 1þ , slight;
2þ , moderate; and 3þ , severe.
Immunohistochemistry
Tissue sections (5 mm) were cut from paraffin blocks, mounted on
slips, and the paraffin was removed by heating in citrate buffer,
pH 6.0. Endogenous peroxidase was blocked with hydrogen
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peroxide 0.3%. Immunohistochemistry was then performed in a
diaminobenzidine tetrahydrochloride (DAKO) autostainer (DAKO,
Copenhagen, Denmark), using an antinitrotyrosine rat polyclonal
antibody from Upstate Biotechnology (Lake Placid, NY, USA) at a
dilution of 1:100. For staining, secondary antibody peroxidase-
labeled polymer and 3,30 DAKO were used. Hemalaun was used for
counterstaining. For quantification, the product of the proportion
of positive cells in quartiles (0,1,2,3,4) and the staining intensity (0-
no staining; 1-weak; 2-moderate; 3-strong) was calculated, yielding a
total immunostaining score ranging from 0 to 12.
BH4 tissue levels
To determine BH4 concentrations, kidney samples were homo-
genized on ice with a microblender in distilled water containing
5 mM dithioerythrol, centrifuged at 12,000 g at 41C for 10 min, and
then subjected to oxidation in acid or base by a method modified
from Fukushima and Nixon.43 To 100 lL supernatant, 20 lL containing
0.5 mol/l HCl and 0.05 mol/l iodine were added for acidic or 20 lL
0.5 mol/l NaOH plus 0.05 mol/l iodine for basic oxidation. After
incubation for 1 h in the dark at room temperature, 20 lL HCl was
added to the basic oxidation only, and all mixtures received 20 lL
0.1 mol/l ascorbic acid for the reduction of excess iodine. Samples
were then centrifuged for 10 min at 12,000 g and 4%C. Biopterin
concentrations were determined by high-performance liquid chro-
matography using 10-lL injection volume, a Nucleosil 10SA column
(250 mm long, 4 mm i.d., Macherey Nagl, Du¨ren, Germany), eluted
with 1.5 ml/min 50 mM potassium phosphate buffer, pH3.0, and
fluorescence detection (excitation 350 nm, emission 440 nm). BH4
concentrations were calculated as the difference in results from
oxidation in acid and base, respectively.
Serum creatinine and urea levels
Before ischemia as well as at serial time points after reperfusion/
transplantation (24, 48 h, and 7 days), blood samples (0.5 ml) were
collected from the retrobulbar venous plexus. Samples were
centrifuged (390 g for 5 min) and plasma concentrations of urea
(U) and creatinine42 were measured using a Hitachi automatic
analyzer (Boehringer Mannheim, Mannheim, Germany).
Statistical analyses
Results are expressed as mean±s.e.m. Statistical analysis was
performed with Prism 5.0 software (GraphPad Software, La Jolla,
CA, USA). When two groups were compared, a two-tailed Student’s
t-test was used. Spearman’s rank coefficient correlation test was used
to examine the relationship between FCD and nitrotyrosine
immunostaining. A P-value of o0.05 was considered to be of
statistical significance.
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